AstraZeneca reports that a Phase III trial of Imfinzi (durvalumab) failed to reach statistical significance for the primary endpoint of progression-free survival (PFS) versus placebo in early-stage non-small cell lung cancer (NSCLC) (IB-IIIA) after complete tumor resection in patients whose tumors express PD-L1 on 25% or more of tumor cells.

We are disappointed by the results of the trial. Imfinzi has helped to change the therapeutic landscape and has achieved several positive results in Phase III trials for patients with earlier-stage lung cancer', commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.

'We remain committed to addressing unmet needs in lung cancer through our extensive development program', she added.

Copyright (c) 2024 All rights reserved.